Comparative Pharmacology
Head-to-head clinical analysis: INPERSOL LC LM W DEXTROSE 1 5 IN PLASTIC CONTAINER versus INPERSOL ZM W DEXTROSE 1 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INPERSOL LC LM W DEXTROSE 1 5 IN PLASTIC CONTAINER versus INPERSOL ZM W DEXTROSE 1 5 IN PLASTIC CONTAINER.
INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER vs INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inpersol-LC/LM with dextrose 1.5% is a peritoneal dialysis solution. The mechanism involves instillation into the peritoneal cavity, where dextrose creates an osmotic gradient that drives ultrafiltration of fluid and removal of uremic toxins (e.g., urea, creatinine) across the peritoneal membrane. The low calcium (LC) and low magnesium (LM) formulation helps prevent hypercalcemia and hypermagnesemia.
Inpersol-ZM w/ Dextrose 1.5% is a peritoneal dialysis solution that acts by creating a concentration gradient across the peritoneal membrane. The dextrose component provides an osmotic driving force that promotes ultrafiltration and removal of waste products (e.g., urea, creatinine) and excess electrolytes from the blood into the dialysate fluid, which is then drained from the peritoneal cavity. The electrolyte composition (sodium, chloride, calcium, magnesium, lactate) helps correct acid-base and electrolyte imbalances.
Intraperitoneal administration: For continuous ambulatory peritoneal dialysis (CAPD), instill 2 liters of 1.5% dextrose solution into the peritoneal cavity via a permanent indwelling catheter. Exchange 4 times per day (every 6 hours) with a dwell time of 4-6 hours. For automated peritoneal dialysis (APD), typical regimen includes 2 liters per cycle with 4-5 cycles overnight and a daytime dwell.
250 mL to 2 L intraperitoneally, instilled over 10-20 minutes, dwell for 4-6 hours, then drain. Typically 4 exchanges per day.
None Documented
None Documented
Not applicable via systemic absorption; glucose absorbed from dialysate exhibits a terminal half-life of 1.5–2 hours in plasma, reflecting rapid cellular uptake and metabolism.
Not applicable systemically; dextrose half-life is minutes due to rapid cellular uptake. In peritoneal dialysis, the half-life of glucose in the peritoneal cavity is approximately 30-60 minutes due to absorption into bloodstream.
Renal: negligible; primarily eliminated via peritoneal dialysis (dialysate outflow). Biliary/fecal: <1%.
Renal: 100% (dialysis fluid containing dextrose is removed directly; glucose is metabolized and not excreted unchanged). Dextrose undergoes cellular metabolism to CO2 and water.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution